Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trynke Hoekstra

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
Diabetes Care|September 3, 2016
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled TrialLennart Tonneijck, Mark M Smits, Marcel H A Muskiet, et al.
Journal of Diabetes and Metabolic Disorders|July 5, 2021
Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The NetherlandsRick I Meijer, Trynke Hoekstra, Niels C Gritters van den Oever, et al.
Diabetes Care|January 25, 2019
Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050Lennart Tonneijck, Mark M Smits, Marcel H A Muskiet, et al.
European Journal of Clinical Investigation|May 24, 2014
Body mass index is related to microvascular vasomotion, this is partly explained by adiponectinMichiel P de Boer, Nienke J Wijnstok, Erik H Serné, et al.
Diabetologia|September 16, 2016
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trialMark M Smits, Lennart Tonneijck, Marcel H A Muskiet, et al.
Transfusion Medicine Reviews|January 3, 2026
Knowledge Related to Blood Donation and Iron, and Willingness to Take Iron Supplements Among Blood Donors in Multiple CountriesFleur Krommendijk, Amber Meulenbeld, Jan Karregat, et al.
Diabetes Care|December 22, 2016
Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled TrialMark M Smits, Lennart Tonneijck, Marcel H A Muskiet, et al.
European Addiction Research|September 30, 2019
The Use of the Alcohol Use Disorders Identification Test - Consumption as an Indicator of Hazardous Alcohol Use among University StudentsSanne Verhoog, Jolien M Dopmeijer, Jannet M de Jonge, et al.
Journal of Hypertension|August 4, 2015
Real-world evidence of suboptimal blood pressure control in patients with type 2 diabetesIris Walraven, M Ruth Mast, Trynke Hoekstra, et al.
Acta Diabetologica|October 8, 2014
Distinct HbA1c trajectories in a type 2 diabetes cohortIris Walraven, M Ruth Mast, Trynke Hoekstra, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Diabetes Care|September 3, 2016
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled TrialLennart Tonneijck, Mark M Smits, Marcel H A Muskiet, et al.
Journal of Diabetes and Metabolic Disorders|July 5, 2021
Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The NetherlandsRick I Meijer, Trynke Hoekstra, Niels C Gritters van den Oever, et al.
Diabetes Care|January 25, 2019
Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050Lennart Tonneijck, Mark M Smits, Marcel H A Muskiet, et al.
European Journal of Clinical Investigation|May 24, 2014
Body mass index is related to microvascular vasomotion, this is partly explained by adiponectinMichiel P de Boer, Nienke J Wijnstok, Erik H Serné, et al.
Diabetologia|September 16, 2016
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trialMark M Smits, Lennart Tonneijck, Marcel H A Muskiet, et al.
Transfusion Medicine Reviews|January 3, 2026
Knowledge Related to Blood Donation and Iron, and Willingness to Take Iron Supplements Among Blood Donors in Multiple CountriesFleur Krommendijk, Amber Meulenbeld, Jan Karregat, et al.
Diabetes Care|December 22, 2016
Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled TrialMark M Smits, Lennart Tonneijck, Marcel H A Muskiet, et al.
European Addiction Research|September 30, 2019
The Use of the Alcohol Use Disorders Identification Test - Consumption as an Indicator of Hazardous Alcohol Use among University StudentsSanne Verhoog, Jolien M Dopmeijer, Jannet M de Jonge, et al.
Journal of Hypertension|August 4, 2015
Real-world evidence of suboptimal blood pressure control in patients with type 2 diabetesIris Walraven, M Ruth Mast, Trynke Hoekstra, et al.
Acta Diabetologica|October 8, 2014
Distinct HbA1c trajectories in a type 2 diabetes cohortIris Walraven, M Ruth Mast, Trynke Hoekstra, et al.
Pageof 13